CMMB - Chemomab rises on patent win covering lead asset

Chemomab Therapeutics (NASDAQ:CMMB), a clinical-stage biotech focused on inflammation and fibrosis, added ~7% in the pre-market Tuesday after the company announced that the U.S. regulators issued a new patent covering its lead drug candidate CM-101. A monoclonal antibody, CM-101, is designed to neutralize CCL24, which is believed to play a role in fibrosis and inflammation. The U.S. Patent No.11365246 is titled "Anti CCL24 (eotaxin 2) Antibodies for Use in the Treatment of Hepatic Disease." The U.S. Patent and Trademark Office issued the patent with a grant date of June 21, 2022. The claims for the patent are expected to expire in 2038 if not for a term extension of up to an additional five years. CM-101 is currently undergoing two mid-stage trials targeted at primary sclerosing cholangitis and liver fibrosis. A Phase 2 trial in systemic sclerosis is expected to begin in late 2022, Chemomab (CMMB) said with its latest earnings release last

For further details see:

Chemomab rises on patent win covering lead asset